FY2027 Earnings Estimate for VRTX Issued By Erste Group Bank

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Erste Group Bank dropped their FY2027 EPS estimates for Vertex Pharmaceuticals in a research note issued to investors on Tuesday, May 12th. Erste Group Bank analyst H. Engel now expects that the pharmaceutical company will post earnings per share of $19.36 for the year, down from their previous estimate of $19.46. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $16.96 per share.

Other equities research analysts have also recently issued reports about the stock. Maxim Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price target for the company in a research report on Wednesday, March 18th. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Oppenheimer increased their price target on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Truist Financial upgraded shares of Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Bank of America increased their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $555.17.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $450.41 on Friday. The stock has a market cap of $114.31 billion, a PE ratio of 26.71, a P/E/G ratio of 1.94 and a beta of 0.30. The stock’s fifty day moving average is $446.38 and its two-hundred day moving average is $450.49. Vertex Pharmaceuticals has a 1-year low of $362.50 and a 1-year high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same period in the previous year, the firm posted $4.06 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 8.3% on a year-over-year basis.

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors have recently made changes to their positions in VRTX. Motiv8 Investments LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $26,000. Colonial Trust Co SC increased its stake in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 38 shares during the last quarter. Swiss RE Ltd. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth $28,000. Eagle Bay Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $29,000. Finally, IMG Wealth Management Inc. raised its holdings in shares of Vertex Pharmaceuticals by 277.8% during the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 50 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Joy Liu sold 1,104 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the sale, the executive vice president directly owned 20,729 shares of the company’s stock, valued at approximately $8,810,239.58. This represents a 5.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Kristen Ambrose sold 223 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $108,456.05. Following the transaction, the chief accounting officer directly owned 6,981 shares in the company, valued at approximately $3,395,209.35. This trade represents a 3.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,802 shares of company stock valued at $37,402,568 over the last quarter. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.